236 related articles for article (PubMed ID: 12387732)
1. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
Jobanputra P; Barton P; Bryan S; Burls A
Health Technol Assess; 2002; 6(21):1-110. PubMed ID: 12387732
[No Abstract] [Full Text] [Related]
2. Etanercept or infliximab: the patient's considerations.
Sherrick RC
Arch Intern Med; 2006 Jul; 166(13):1418; author reply 1418. PubMed ID: 16832010
[No Abstract] [Full Text] [Related]
3. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].
Kondo H
Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):153-60. PubMed ID: 14968591
[No Abstract] [Full Text] [Related]
5. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
Richard-Miceli C; Dougados M
BioDrugs; 2001; 15(4):251-9. PubMed ID: 11437690
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of TNF antagonists in routine clinical practice and costs].
Prokes M
Vnitr Lek; 2009 Jan; 55(1):45-53. PubMed ID: 19227955
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
[TBL] [Abstract][Full Text] [Related]
8. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
Kobelt G; Eberhardt K; Geborek P
Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
10. Etanercept and infliximab for rheumatoid arthritis.
Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
[TBL] [Abstract][Full Text] [Related]
11. [Anti-rheumatoid biologics and pharmacoeconomic evaluation].
Tsutani K; Igarashi A
Nihon Rinsho; 2005 Jan; 63 Suppl 1():711-8. PubMed ID: 15799447
[No Abstract] [Full Text] [Related]
12. Estimated medication costs of primary TNFα antagonist failure in patients with rheumatoid arthritis.
Rose E; Lequerré T; Pouplin S; Daragon A; Le Loët X; Vittecoq O
Joint Bone Spine; 2012 Jul; 79(4):421-2. PubMed ID: 22512937
[No Abstract] [Full Text] [Related]
13. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
Spalding JR; Hay J
Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
[TBL] [Abstract][Full Text] [Related]
14. "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate.
Hochberg MC; Tracy JK; Flores RH
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii51-4. PubMed ID: 11890654
[No Abstract] [Full Text] [Related]
15. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
[TBL] [Abstract][Full Text] [Related]
16. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis.
Seriolo B; Paolino S; Ferrone C; Cutolo M
Clin Rheumatol; 2007 Oct; 26(10):1799-800. PubMed ID: 17646897
[No Abstract] [Full Text] [Related]
17. [TNF targetting therapy for rheumatoid arthritis].
Takeuchi T
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1787-94. PubMed ID: 17037316
[No Abstract] [Full Text] [Related]
18. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
Weycker D; Yu EB; Woolley JM; Oster G
Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
[TBL] [Abstract][Full Text] [Related]
20. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?
Yazici Y; Erkan D
Ann Rheum Dis; 2004 May; 63(5):607-8; author reply 608. PubMed ID: 15082503
[No Abstract] [Full Text] [Related]
[Next] [New Search]
